| Literature DB >> 32316331 |
Jagoda Goślińska1, Agnieszka Wareńczak1, Margaret Miedzyblocki1, Krystyna Hejdysz1, Ewa Adamczyk1, Paweł Sip1, Ewa Chlebuś1, Jarosław Gośliński2, Piotr Owczarek2, Adam Woźniak2, Przemysław Lisiński1.
Abstract
Osteoarthritis of the knee (OAK) is characterized by pain, limitation of joint mobility, and significant deterioration of proprioception resulting in functional decline. This study assessed proprioception in OAK patients following two ten-day rehabilitation programs using the Orthyo® system. Fifty-four study participants with clinical symptoms and radiological signs of OAK were randomly divided into an exercise group (n = 27) or a manual therapy group (n = 27). The control group consisted of 27 volunteers with radiological signs of OAK, but with no clinical symptoms or prior history of rehabilitation. The following parameters were assessed: knee proprioception using inertial sensors and a mobile application, patients' function using Western Ontario and McMaster Universities osteoarthritis index (WOMAC), and pain intensity using the visual analog scale (VAS). Following rehabilitation, knee proprioception tests did not improve in either study group. Both study groups showed significant improvement of the WOMAC-assessed function (exercise group: p < 0.01, manual therapy group: p = 0.01) and a significant decrease (p < 0.01) of VAS-assessed pain following rehabilitation, but the post-therapy results did not differ significantly between the aforementioned groups. The Orthyo® system provided a quick and accurate assessment of the knee joint position sense. There was no direct relationship between functionality, pain, and proprioception threshold in the knee joint.Entities:
Keywords: knee joint; mobile applications; osteoarthritis; proprioception; wireless sensors
Year: 2020 PMID: 32316331 PMCID: PMC7219042 DOI: 10.3390/s20082268
Source DB: PubMed Journal: Sensors (Basel) ISSN: 1424-8220 Impact factor: 3.576
Main anthropometric data of the study population (only included patients).
| Variable | Group | No. | Mean ± SD | Median | Min–Max | |
|---|---|---|---|---|---|---|
| age (years) | E | 27 | 65.0 ± 7.4 | 64.0 | 55.0–78.0 | 0.10 |
| MT | 27 | 66.1 ± 4.7 | 65.0 | 58.0–76.0 | ||
| C | 27 | 63.0 ± 6.6 | 60.0 | 53.0–76.0 | ||
| weight (kg) | E | 27 | 76.1 ± 11.3 | 75.0 | 58.0–100.0 | 0.52 |
| MT | 27 | 76.2 ± 11.5 | 75.0 | 58.0–105.0 | ||
| C | 27 | 73.5 ± 12.3 | 68.0 | 56.0–90.0 | ||
| height (m) | E | 27 | 1.67 ± 0.07 | 1.66 | 1.53–1.82 | 0.69 |
| MT | 27 | 1.66 ± 0.07 | 1.66 | 1.55–1.82 | ||
| C | 27 | 1.68 ± 0.07 | 1.67 | 1.56–1.80 | ||
| BMI (kg/m2) | E | 27 | 27.3 ± 3.8 | 26.8 | 20.4–36.1 | 0.07 |
| MT | 27 | 27.6 ± 4.0 | 26.9 | 20.9–38.3 | ||
| C | 27 | 25.9 ± 3.8 | 24.5 | 20.5–34.3 |
p-value: the comparison of intergroup age, weight, height, and BMI (Kruskal-Wallis test) E – group treated with synergistic exercises in a closed kinematic chain, MT – group treated with manual therapy, C – control group
Figure 1Placement of Orthyo® system sensors on the lower extremity.
Figure 2Exercise protocol for the ball-rolling task.
Figure 3Exercises on the sensorimotor cushion.
Results of proprioception evaluation (end angle for JPS test and MSE) in E, MT, and C groups of participants.
| Variable | Group | Before | After | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean ± SD | Median | Range | Mean ± SD | Median | Range | |||||
| End angle (°) | E | 67.0 ± 9.3 | 66.6 | 51.6–87.0 | 0.31 | 67.4 ± 7.5 a | 68.1 | 52.9–86.4 | 0.04 | 0.84 |
| MT. | 67.0 ± 9.1 | 66.7 | 46.3–85.8 | 72.7 ± 9.5 a | 71.4 | 48.2–101.7 | 0.02 * | |||
| C | 69.9 ± 6.5 | 72.3 | 54.9–77.7 | 69.5 ± 10.7 | 669.0 | 50.9–98.0 | 0.65 * | |||
| End angle (°) | E | 68.4 ± 9.3 | 67.7 | 46.6–85.6 | 0.99 | 68.3 ± 8.4 | 69.1 | 44.2–86.7 | 0.88 | 0.63 * |
| MT. | 70.4 ± 12.9 | 68.4 | 53.0–107.6 | 68.8 ± 11.2 | 66.6 | 47.6–98.5 | 0.53 | |||
| C | 69.1 ± 8.1 | 68.4 | 59.1–87.8 | 67.4 ± 7.0 | 70.5 | 51.5–76.6 | 0.29 | |||
| E | 11.0 ± 13.6 | 4.0 | 0–40.8 | 0.38 | 6.8 ± 5.4 | 6.7 | 0–17.0 | 0.96 | 0.33 * | |
| MT. | 8.4 ± 15.1 | 4.1 | 0.4–79.4 | 10.3 ± 16.5 | 3.6 | 0.3–78.2 | 0.27 * | |||
| C | 6.0 ± 8.7 | 3.1 | 0.1–32.3 | 9.7 ± 11.0 | 5.0 | 0.1–32.2 | 0.26 * | |||
| E | 6.6 ± 8.7 | 2.9 | 0.1–33.9 | 0.41 | 5.1 ± 7.1 | 3.3 | 0.1–36.4 | 0.47 | 0.39 * | |
| MT. | 5.2 ± 5.5 | 4.0 | 0–27.1 | 5.2 ± 4.9 | 3.8 | 0.1–15.9 | 0.77 * | |||
| C | 9.6 ± 9.7 | 7.5 | 0.1–32.8 | 7.3 ± 7.0 | 6.2 | 5.90–25.8 | 0.22 | |||
p-value1—the comparison of intergroup end-angle and MSE pre-treatment (Kruskal-Wallis test); p-value2—the comparison of intergroup end-angle and MSE post-treatment (Kruskal-Wallis test); p-value3—the comparison of intragroup end-angle and MSE pre- and post-treatment (dependent t-student test or * Wilcoxon signed ranked test); a—posthoc analysis.
Results of WOMAC measure in E, MT, and C groups of participants.
| Variable | Group | Before | After | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean ± SD | Median | Range | Mean ± SD | Median | Range | |||||
| WOMAC | E | 45.9 ± 13.7 a | 42.0 | 19.0–65.0 | <0.01 | 39.7 ± 12.8 a | 45.0 | 12.0–58.0 | <0.01 | <0.01 |
| MT. | 46.3 ± 19.0 b | 44.0 | 2.0–81.0 | 40.1 ± 21.7 b | 33.0 | 1.0–84.0 | 0.01 | |||
| C | 19.3 ± 17.6 a,b | 13.0 | 2.0–78.0 | 18.4 ± 18.6 a,b | 12.0 | 1.0–75.0 | 0.11 * | |||
p-value1—the comparison of intergroup WOMAC pre-treatment (Kruskal-Wallis test or Mann-Whitney U test); p-value2—the comparison of intergroup WOMAC post-treatment (Kruskal-Wallis test or Mann-Whitney U test); p-value3—the comparison of intragroup WOMAC pre- and post-treatment (dependent t-student test or * Wilcoxon signed ranked test); a,b—posthoc analysis.
Results of VAS scales in E, MT, and C groups of participants.
| Variable | Group | Before | After | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean ± SD | Median | Range | Mean ± SD | Median | Range | |||||
| VAS left | E | 5.2 ± 2.7 a | 6.0 | 0–10.0 | 0.99 | 3.4 ± 2.1 a | 3.0 | 0–9.0 | 0.72 | <0.01 * |
| MT. | 5.2 ± 2.4 b | 6.0 | 0–8.0 | 3.2 ± 2.7 b | 3.0 | 0–8.0 | <0.01 * | |||
| VAS right | E | 5.0 ± 2.7 a | 5.0 | 0–10.0 | 0.89 | 3.4 ± 2.2 a | 3.0 | 0–9.0 | 0.56 | <0.01 * |
| MT. | 4.9 ± 2.7 b | 5.0 | 0–9.0 | 3.0 ± 2.6 | 2.0 | 0–8.0 | <0.01 | |||
p-value1—the comparison of intergroup VAS pre-treatment (Kruskal-Wallis test or Mann–Whitney U test); p-value2—the comparison of intergroup VAS post-treatment (Kruskal-Wallis test or Mann-Whitney U test); p-value3—the comparison of intragroup VAS pre- and post-treatment (dependent t-student test or * Wilcoxon signed ranked test); a,b—posthoc analysis.